

Department of Medicine - Publications 2009

Autexier, Chantal

--Marie-Egyptienne DT, Brault ME, Nimmo GAM, Londoño-Vallejo JA and **Autexier C.** Growth defects in mouse cells expressing mutant-template mouse telomerase RNA. *Cancer Lett*, 275:266-276, 2009

Baron, Murray

--**Baron M**, Schieir O, **Hudson M**, Steele R, Janelle-Montcalm A, Bernstein J, Starr M, Gagné M, Stein M, Kang H, Kapusta M, Couture F, Fitzcharles MA, Garfield B, Ménard HA, Berkson L, Pineau C, Gutkowski A, Zummer M, Mathieu JP, Mercille S, Ligier S, Krasny J, Bertrand C, Yuen SY, Schulz J. Evaluation of the clinimetric properties of the Early Inflammatory Arthritis-Self-administered Comorbidity Questionnaire. *Rheumatology*, 48:390-4, 2009

--**Baron M**, **Hudson M**, Canadian Scleroderma Research Group, Steele R. Malnutrition is common in systemic sclerosis: results from the Canadian scleroderma research group database. *J Rheumatol*, 36:2737-43, 2009

--**Baron M**, Hudson M, Steele R. Malnutrition is common in systemic sclerosis: results from the Canadian Scleroderma research group database. *J Rheumatol*, 36:2737-43, 2009

--Chung L, Shapiro L, Fiorentino D, **Baron M**, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin RW, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Gilbert A, Dechow FJ, Gregory J, Wigley FM. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. *Arthritis Rheum*, 60:870-7, 2009

--Dobkin PL, De Civita M, Bernatsky S, Filipski M, Sita A, **Baron M.** Preliminary validity of the barriers to treatment adherence questionnaire in fibromyalgia: combining quantitative and focus group data. *Psychol Rep*, 105:447-60, 2009

--Fan X, Pope J, **Baron M.** What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG). *Rheumatol Int* 2009

--Feldman DE, Schieir O, Montcalm AJ, Bernatsky S, **Baron M.** Rapidity of rheumatology consultation for people in an early inflammatory arthritis cohort. *Ann Rheum Dis*, 68:1790-1, 2009

--Lawrence E, Pope J, Al Zahraly Z, Lalani S, **Baron M.** The relationship between changes in self-reported disability (measured by the Health Assessment Questionnaire - HAQ) in Scleroderma and improvement of disease status in clinical practice. *Clin Exp Rheumatol*, 27(3 Suppl 54):32-7, 2009

Brewer, Timothy

--**Brewer TF**, Saba N, Clair V. From boutique to basic: a call for standardized medical education in global health. *Med Education*, 43:930-933, 2009

Cohen, Albert

--Villani A-C, Lemire M, Fortin G, Louis E, Silverberg MS, Collette C, Baba N, Libioulle C, Belaiche J, Bitton A, Gaudet D, **Cohen A**, Langelier D, Fortin PR, Wither JE, Sarfati M, Rutgeerts P, Rioux JD, Vermeire S, Hudson TJ, Franchimont D. Common Variants in the NLRP3 region contribute to Crohn's disease susceptibility. *Nature Genetics*, 41:71-6, 2009

Chertkow, Howard

--Richards BA, **Chertkow H**, Singh V, Robillard A, Massoud F, & Kabani NJ. Patterns of cortical thinning in Alzheimer's disease and Fronto-temporal dementia. *Neurobiology of Aging*, 30:1626-36, 2009

--Maes OC, **Chertkow H**, Wang E and Schipper HM. MicroRNA: Implications for Alzheimer Disease and other human CNS disorders. *Current Genomics*. 10:154-168, 2009

--Burns DH, Rosendahl S, Bandilla D, Maes OC, **Chertkow H**, Schipper HM. Near-infrared spectroscopy of blood plasma for diagnosis of sporadic Alzheimer Disease. *Journal of Alzheimer's Disease*, 17:391-397, 2009

--Johns E K, Phillips NA, Belleville S, Goupil D, Babins L, Kelner N, Ska B, Gilbert B, Inglis G, Panisset M, de Boysson C, & **Chertkow H**. Executive functions in frontotemporal dementia and Lewy body dementia. *Neuropsychology*, 23:765-777, 2009

Cohen, Robin

--Stajduhar KS and **Cohen SR**. Family carers in the home. In: Family Carers in Palliative Care. Eds. P. Hudson and S Payne. Oxford University Press, Oxford, England, pp 149-168, 2009

--*Mehta A, **Cohen SR**, *Chan LS. Palliative care: A need for a family systems approach. *Palliative and Supportive Care*, 7:235-243, 2009

--*Chan L, Macdonald ME, **Cohen SR**. Moving culture beyond ethnicity: Examining dying in hospital through a cultural lens. *Journal of Palliative Care*, 25:117-124, 2009

--Larue C, Loiselle C., Bonin JP, **Cohen R**, Gélinas C, Dubois S, Lambert S. Les méthodes mixtes : Stratégies prometteuses pour l'évaluation des interventions infirmières. *Recherche en soins infirmiers*. 97:50-62, 2009

Davidman, Michael

--Fellstrom BC et al (including **Davidman, M.**) AURORA Study Group Investigators. Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. *N Engl J Med*, 360:1395-407, 2009

Eisenberg, Mark J.

--Filion KB, Roy AM, Baboushkin T, Rinfret S, **Eisenberg MJ**. Cost-effectiveness of drug-eluting stents including the economic impact of late stent thrombosis. *Am J Cardiol* 103:338-44, 2009

--Afilalo J, Roy M, **Eisenberg MJ**. Systematic review of fibrinolytic-facilitated percutaneous coronary intervention: Potential benefits and future challenges. *Can J Cardiol* 25:141-8, 2009

--Mottillo S, Filion KB, Bélisle P, Joseph L, Gervais A, O'Loughlin J, Paradis G, Pihl R, Pilote L, Rinfret S, Tremblay M, **Eisenberg MJ**. Behavioral interventions for smoking cessation: A meta-analysis of randomized controlled trials. *Eur Heart J* 30:718-30, 2009

--**Eisenberg MJ**, Richard P, Libersan D, Filion KB. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. *Circulation* 119:1634-42, 2009

--Afilalo J, Karunanathan S, **Eisenberg MJ**, Alexander KP, Bergman H. The role of frailty in patients with cardiovascular disease. *Am J Cardiol* 103:1616-21, 2009

--Thanassoulis G, Karp I, Humphries K, Tu J, **Eisenberg MJ**, Pilote L. Impact of restrictive prescription plans on heart failure medication use. *Circ Cardiovasc Qual Outcomes* 2:484-90, 2009

--Khan R, Rawal S, **Eisenberg MJ**. Transitioning from 16-slice to 64-slice multi-detector computed tomography for the assessment of coronary artery disease: Are we really making progress? *Can J Cardiol* 25:533-42, 2009

--McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, **Eisenberg MJ**, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ; ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. *Circulation* 119:2250-94, 2009

--Donath E, Filion KB, **Eisenberg MJ**. Improving the clinician-scientist pathway: a survey of clinician-scientists. *Arch Intern Med*, 169:1242-4, 2009

Elizov, Michelle

--Y. Steinert, P.J. McLeod, M. Boillat, S. Meterissian, **M. Elizov**, M.E. Macdonald. Faculty Development: a 'Field of Dreams?' *Medical Education*, 43:1:42-49, 2009

Foulkes, William

--Ginsburg O, Ghadirian P, Lubinski J, Cybulski C, Lynch H, Neuhausen S, Kim-Sing C, Robson M, Domchek S, Isaacs C, Klijn J, Armel S, **Foulkes WD**, Tung N, Moller P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. *Breast Cancer Res Treat*, 114:1:127-35, 2009

--Baker K, **Foulkes WD**, Jass JR. MSI-H colorectal cancers preferentially retain and expand intraepithelial lymphocytes rather than peripherally derived CD8+ T cells. *Cancer Immunol Immunother*, 58(1):135-44, 2009

--**Foulkes WD**, Grainge MJ, Rakha EA, Green AR, Ellis IO. Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. *Breast Cancer Res Treat*, 117:1:199-204., 2009

--Arnes JB, Bégin LR, Stefansson I, Brunet JS, Nielsen TO, **Foulkes WD**, Akslen LA. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer. *J Clin Pathol*, 62:2:139-46, 2009

--Novak DJ, Sabbaghian N, Maillet P, Chappuis PO, **Foulkes WD**, **Tischkowitz M**. Analysis of the genes coding for the BRCA1-interacting proteins, RAP80 and Abraxas (CCDC98), in high-risk, non-BRCA1/2, multiethnic breast cancer cases. *Breast Cancer Res Treat*, 117:2:453-9, 2009

--Pouchet CJ, Wong N, Chong G, Sheehan MJ, Schneider G, Rosen-Sheidley B, **Foulkes W**, **Tischkowitz M**. A comparison of models used to predict MLH1, MSH2 and MSH6 mutation carriers. *Ann Oncol*, 20:4:681-8, 2009

--Al-Thihli K, Palma L, Marcus V, Cesari M, Kushner YB, Barkun A, **Foulkes WD**. A case of Cowden's syndrome presenting with gastric carcinomas and gastrointestinal polyposis. *Nat Clin Pract Gastroenterol Hepatol*, 6:3:184-9, 2009

--Vigano A, Trutschnigg B, Kilgour RD, Hamel N, Hornby L, Lucar E, **Foulkes W**, Tremblay ML, Morais JA. Relationship between angiotensin-converting enzyme gene polymorphism and body composition, functional performance, and blood biomarkers in advanced cancer patients. *Clin Cancer Res*, 15:7:2442-7, 2009

--Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, **Foulkes WD**, Ellis IO. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. *Clin Cancer Res*, 15:7:2302-10, 2009

--Chong G, Jarry J, Marcus V, Thiffault I, Winocour S, Monczak Y, Drouin R, Latreille J, Australie K, Bapat B, Gordon PH, Giguère Y, Gologan A, Galiatsatos P, Jass JR, Wong N, Zaor S, Palma L, Kasprzak L, **Tischkowitz M**, **Foulkes WD**. High frequency of exon deletions and putative founder effects in French Canadian Lynch syndrome families. *Hum Mutat*, 30:8:E797-812, 2009

--Vicus D, Rosen B, Lubinski J, Domchek S, Kauff ND, Lynch HT, Isaacs C, Tung N, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group. Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. *Gynecol Oncol*, 115:1:135-7, 2009

--Wong Wong Keet A, Al-Rafae M, Chappuis PO, Brunet JS, Ghadirian P, **Foulkes WD**. Long-term outcome after neo-adjuvant chemotherapy for breast cancer in BRCA1/2 carriers. *Int J Cancer*, 125:9:2236-8, 2009

--Huang F, Kushner YB, Langleben A, **Foulkes WD**; Medscape. Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer. *Nat Rev Clin Oncol*, 6:8:488-92, 2009 Review.

--Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, Ostrander EA, Ingles SA, John EM, Thibodeau SN, Schaid D, Park JY, Spurdle A, Clements J, Dickinson JL, Maier C, Vogel W, Dörk T, Rebbeck TR, Cooney KA, Cannon-Albright L, Chappuis PO, Hutter P, Zeegers M, Kaneva R, Zhang HW, Lu YJ, **Foulkes WD**, English DR, Leongamornlert DA, Tymrakiewicz M, Morrison J, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Saunders EJ, Page EC, Sawyer EJ, Edwards SM, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Southey MC, Lophatananon A, Liu JF, Kolonel LN, Le Marchand L, Wahlfors T, Tammela TL, Auvinen A, Lewis SJ, Cox A, FitzGerald LM, Koopmeiners JS, Karyadi DM, Kwon EM, Stern MC, Corral R, Joshi AD, Shahabi A, McDonnell SK, Sellers TA, Pow-Sang J, Chambers S, Aitken J, Gardiner RA, Batra J, Kedda MA, Lose F, Polanowski A, Patterson B, Serth J, Meyer A, Luedeke M, Stefflova K, Ray AM, Lange EM, Farnham J, Khan H, Slavov C, Mitkova A, Cao G; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. *Nat Genet*, 41:10:1116-21, 2009

--Li L, Biswas K, Habib LA, Kuznetsov SG, Hamel N, Kirchhoff T, Wong N, Armel S, Chong G, Narod SA, Claes K, Offit K, Robson ME, Stauffer S, Sharan SK, **Foulkes WD**. Functional redundancy of exon 12 of BRCA2 revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant. *Hum Mutat*, 30:11:1543-50, 2009

--Hamilton LJ, Evans AJ, Cornford EJ, Rakha EA, Ellis IO, **Foulkes WD**. Will MRI screening deliver the expected survival advantage in BRCA 1 carriers? *Clin Radiol*, 64:11:1045-7., 2009

--Ghadirian P, Robidoux A, Zhang P, Royer R, Akbari M, Zhang S, Fafard E, Costa M, Martin G, Potvin C, Patocskaï E, Larouche N, Younan R, Nassif E, Giroux S, Narod SA, Rousseau F, **Foulkes WD**. The contribution of founder mutations to early-onset breast cancer in French-Canadian women. *Clin Genet*, 76:5:421-6, 2009

Gatignol, Anne

--Daher A, Laraki G, Singh M, Melendez-Peña CE, Bannwarth S, Peters AH, Meurs EF, Braun RE, Patel RC, and **Gatignol A**. TRBP control of PACT-induced phosphorylation of PKR is reversed by stress. *Mol. Cell. Biol.* 29:254-265. 2009

--Daniels SM, Melendez-Peña CE, Scarborough RJ, Daher A, Christensen HS, El Far M, Purcell DF, Lainé S and **Gatignol A**. Characterization of the TRBP domain required for Dicer interaction and function in RNA interference. *BMC Mol. Biol.* 10:38. 2009

--Clerzius G, Gélinas J-F, Daher A, Bonnet M, Meurs EF, and **Gatignol A**. ADAR1 interacts with PKR during HIV infection of lymphocytes and contributes to viral replication. *J. Virol.* 83: 10119-10128. 2009

Greenaway, Christina

Houston S. An Advisory Committee Statement for the Committee to Advise on Tropical Medicine and Travel (CATMAT) (including **C Greenaway**). Risk Assessment and Prevention of Tuberculosis among Travelers. *Can Comm Disease Report*, 35:1-19, 2009

Joyal, Dominique

--Nagano N, Morin JF, **Joyal D**, **Rudski L**. Acute myocardial infarction and limb ischemia as manifestation of nonbacterial thrombotic endocarditis. *ZJ Thorac Cardiovasc Surg*, 137:1278-80, 2009

Hoffer, L. John

--Robitaille R, Mamer OA, Miller WH Jr, Levine M, Melnychuk D, Rousseau C, **Hoffer LJ**. Oxalic acid excretion following intravenous ascorbic acid administration. *Metabolism*, 58:263-269, 2009

--Robitaille L, **Hoffer LJ**, Levine M. Oxalic acid excretion after intravenous ascorbic acid administration. *Metabolism* 58:888-889, 2009, letter

--**Hoffer LJ**. The need for consistent criteria for identifying malnutrition. IN: *The Economic Medical/Scientific and Regulatory Aspects of Clinical Nutrition Practice: What Impacts What?* 12th Nestlé Nutrition Workshop Series Clinical & Performance Program, Basel, Karger, 41-52, 2009

Hudson, Marie

--Razykov I, Thombs BD, **Hudson M**, Bassel M, Canadian Scleroderma Research Group, Baron M. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. *Arthritis Rheum*, 61:1765-70, 2009

--**Hudson M**, Steele R, Lu Y, Thombs BD, Canadian Scleroderma Research Group, Baron M. Work Disability in Systemic Sclerosis. *J Rheumatol*, 36:2481-6, 2009

--**Hudson M**, Thombs BD, Steele R, Panopalis P, Newton E, Canadian Scleroderma Research Group, Baron M. Health-Related Quality of Life in Systemic Sclerosis: A Systematic Review. *Arthritis Rheum*, 61:1112-1120, 2009

--**Hudson M**, Steele R, Lu Y, Canadian Scleroderma Research Group, Baron M. Research letter – Hypocomplementemia in Systemic Sclerosis. *Reumatismo*, 61:156-8, 2009

--Thombs B, **Hudson M**, Bassel M, Taillefer SS, Canadian Scleroderma Research Group, Baron M. Sociodemographic, Disease and Symptom Correlates of Fatigue in Systemic Sclerosis: Evidence from a Sample of 659 Canadian Scleroderma Research Group Registry Patients. *Arthritis Rheum*, 61:966-973, 2009

--**Hudson M**, Sharma A, Bernstein B, Canadian Scleroderma Research Group, Baron M. Validity of Self-Reported Comorbidities in Systemic Sclerosis. *J Rheumatol*, 36:1477-80, 2009

--**Hudson M**, Steele R, Lu Y, Thombs BD, Panopalis P, Canadian Scleroderma Research Group, Baron M. Clinical Correlates of Self-Reported Physical Health Status in Systemic Sclerosis. *J Rheumatol*, 36:1226-9, 2009

--Knafo R, Thombs BD, Jewett L, **Hudson M**, Wigley F, Haythornthwaite JA. (Not) talking about sex: a systematic comparison of sexual impairment in women with systemic sclerosis and other chronic disease samples. *Rheumatology (Oxford)*, 48:1300-3, 2009

--Law G, Pope J, Lalani S, Silverman E, Cooper G, Fortin PR, Zummer M, Smith CD, Petty R, Tucker L, Albert L, Huber A, Ramsey S, Arbillaga A, Chedéville G, **Hudson M**, CaNIOS Investigators, Peschken C. Barriers to Healthcare in a Multiethnic Cohort of Systemic Lupus Erythematosus (SLE) patients: Patient and Physician Perceptions. *Clinical Medicine: Arthritis and Musculoskeletal Disorders*, 2:1-8.

--Bernier MO, Mikaeloff Y, **Hudson M**, Suissa S. Combined Oral Contraceptive Use and the Risk of Systemic Lupus Erythematosus. *Arthritis Rheumatism*, 61:476-8, 2009

--Peschken C, Katz S, Silverman E, Pope J, Fortin P, Pineau C, Smith D, Arbillaga H, Gladman D, Urowitz M, Zummer M, Clarke A, Bernatsky S, **Hudson M**, CaNIOS Investigators. The 1000 Canadian Faces of Lupus: Determinants of Disease Outcome in a Large Multi-Ethnic Cohort. *J Rheumatology*, 36:1200-8, 2009

--Bernatsky S, Joseph L, Pineau CA, Belisle P, **Hudson M**, Clarke AE. Scleroderma Prevalence: Demographic Variations in a Population-Based Sample. *Arthritis Rheumatism*, 61:400-404.

--**Hudson M**, Thombs BD, Steele R, Panopalis P, Newton E, Canadian Scleroderma Research Group, Murray Baron. Quality of life in systemic sclerosis compared to the general population and patients with other chronic conditions. *J Rheumatology*, 36:768-72, 2009

--**Hudson M**, Thombs B, Canadian Scleroderma Research Group, Baron M. Time to Diagnosis in Systemic Sclerosis: Is Gender a Factor? *Arthritis Rheumatism*, 61:274-278, 2009

--Bernatsky S, **Hudson M**, Panopolis P, Clarke A, Pope J, LeClercq S, St. Pierre Y, Canadian Scleroderma Research Group, Baron M. The Cost of Systemic Sclerosis. *Arthritis Rheum*, 61:119-123, 2009

--Bernatsky S, **Hudson M**, Pope J, Markland J, Robinson D, Jones N, Docherty P, Abu-Hakima M, Leclerc S, Dunne J, Smith CD, Sutton E, Khalidi N, Mathieu JP, Masetto A, Ligier S, Kaminska E, Baron M; the Canadian Scleroderma Research Group. Reports of abnormal cervical cancer screening tests in systemic sclerosis. *Rheumatology*, 48:149-51, 2009

--Shieir O, Thombs B, **Hudson M**, Taillefer S, Steele R, Berkson L, Bertrand C, Couture F, Fitzcharles M-A, Gagne M, Garfield B, Gutkowski A, Kang H, Kapusta M, Ligier S, Mathieu J-P, Menard H, Mercille S, Starr M, Stein M, Zummer M, Baron M. Symptoms of Depression Predict the trajectory of Pain Among Patients with Early Inflammatory Arthritis: A Path Analysis Approach to Assessing Change. *J Rheumatol*, 36:231-9, 2009

--Bernatsky S, Panopolis P, **Hudson M**, Pope J, Leclercq S, Robinson D, Jones N, Markland J, Abu-Hakima M, Mathieu JP, Docherty P, Khalidi N, Sutton E, Baron M. Demographic and Clinical Factors Associated with Physician Service Use in Systemic Sclerosis. *J Rheumatol*, 36:96-8, 2009

Kahn, Susan

--Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; RE-COVER Study Group (includes **Kahn S**). "Dabigatran versus warfarin in the treatment of acute venous thromboembolism. *NEJM*, 361(24):2342-2352, 2009

--Couturaud F, Leroyer C, Julian JA, **Kahn SR**, Ginsberg JS, Wells PS, Douketis JD, Mottier D, Kearon C. Factors that predict risk of thrombosis in relatives of patients with unprovoked venous thromboembolism. *Chest*, 136:6:1537-1545, 2009

--**Kahn SR**. How I manage the post-thrombotic syndrome. *Blood*, 114:4624-4631, 2009

--Shrier I, **Kahn SR**, Steele RJ. Effect of early physical activity on long term outcome after venous thrombosis. *Clinical Journal of Sport Medicine*, 19:487-493, 2009

--Wells PS, Louzada ML, Taljaard M, Anderson DR, **Kahn SR**, Langlois NJ, Rutberg J, Kovacs MJ, Rodger MA. A pilot study to assess the feasibility of a multicenter cluster randomized trial for the management of asymptomatic persons with a thrombophilia. *Journal of Genetic Counseling*, 18:475-482, 2009

--**Kahn SR**. Post-thrombotic syndrome after deep venous thrombosis: risk factors, prevention, and therapeutic options. *Clin Adv Hematol Oncol*, 7:433-435, 2009

--Kramer MS, **Kahn SR**, Platt RW, Genest J, Rozen R, Chen MF, Goulet L, Séguin L, Dassa C, Lydon J, McNamara H, Dahhou M, Lamoureux J, and Evans RW. Antioxidant vitamins, long-chain fatty acids, and spontaneous preterm birth. *Epidemiology*, 20:707-13, 2009

--Hull RD, Pineo GF, Brant R, Liang J, Cook R, Solymoss S, Poon M-C, Raskob G and LITE Trial Investigators (includes **Kahn SR**). Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. *Am J Med*, 122:762-769, 2009

--Kramer MS, Wilkins R, Goulet L, Séguin L, Lydon J, **Kahn SR**, McNamara H, Dassa C, Dahhou M, Masse A, Miner L, Asselin G, Gauthier H, Ghanem A, Benjamin A and Platt RW for the Montreal Prematurity Study Group. Investigating socioeconomic disparities in preterm birth: Evidence for selective study participation and selection bias. *Paediatric and Perinatal Epidemiology*, 23:301-309, 2009

--Kramer MS, **Kahn SR**, Rozen R, Evans R, Platt RW, Chen MF, Goulet L, Séguin L, Dassa C, Lydon J, McNamara H, Dahhou M and Genest J. Vasculopathic and thrombophilic risk factors for spontaneous preterm birth. *Int J Epidemiol*, 38:715-723, 2009

--Prins MH, Guillemin I, Gilet H, Gabriel S, Essers B, Raskob G, **Kahn SR**. Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q©). *Health Qual Life Outcomes*, 7:30, 2009

--Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD for the RECORD4 Investigators, includes **Kahn SR**. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomized trial. *The Lancet*, 373:1673-80, 2009

--Kaufman JA, Rundback JH, Kee ST, Geerts W, Gillespie D, **Kahn SR**, Kearon C, Rectenwald J, Rogers FB, Stavropoulos SW, Streiff M, Vedantham S, Venbrux A. Development of a Research Agenda for Inferior Vena Cava Filters: Proceedings from a Multidisciplinary Research Consensus Panel. *J Vasc Interv Radiol*, 20:697-707, 2009

--Kramer MS, Lydon J, Séguin L, Goulet L, **Kahn SR**, McNamara H, Genest J, Dassa C, Chen MF, Sharma S, Meaney MJ, Thomson S, Van Um S, Koren G, Dahhou M, Lamoureux J, Platt RW. Stress pathways to spontaneous preterm birth. The role of stressors, psychological distress, and stress hormones. *American Journal of Epidemiology*, 169:1319-1326, 2009

--Prandoni P and **Kahn SR**. Post thrombotic syndrome: prevalence, prognostication and need for progress. *Br J Haem*, 145:286-295, 2009

--**Kahn SR**. Measurement properties of the Villalta Scale to define and classify the severity of the post-thrombotic syndrome. *J Thromb Haemost*, 7:884-888, 2009

--Le Gal G, Kovacs MJ, Carrier M, Do K, **Kahn SR**, Wells PS, Anderson DA, Chagnon I, Solymoss S, Crowther M, Righini M, Perrier A, White RH, Vickars L, Rodger M. Validation of a Diagnostic Approach to Exclude Recurrent Venous Thromboembolism. *J Thromb Haemost*, 7:752-759, 2009

--**Kahn SR**, Partsch H, Vedantham S, Prandoni P, Kearon C on behalf of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of post-thrombotic syndrome of the leg for use in clinical investigations: A recommendation for standardization. *J Thromb Haemost*, 7:879-883, 2009

--Crowther MA, Ageno W, Garcia D, Wang L, Witt DM, Clark NP, Blostein M, **Kahn SR**, Schulman S, Kovacs MJ, Wells P, Anderson D, Kearon C, Ginsberg J, Selby R, , Siragusa S, Silingardi M, Dowd MB, Rodger M. Oral vitamin K does not significantly reduce bleeding in excessively anticoagulated patients on Warfarin: Results of a randomized, controlled trial. *Annals Intern Med*, 150:293-300, 2009

--*Shbaklo H, Holcroft CA, **Kahn SR**. Levels of Inflammatory Markers and the Development of the Post Thrombotic Syndrome. *Thromb Haemost*, 101:505-512, 2009

--**Kahn SR**, Platt R, McNamara H, Rozen R, Chen MF, Genest J Jr., Goulet L, Lydon J, Seguin L, Dassa C, Masse A, Asselin G, Benjamin A, Miner L, Ghanem A, Kramer MS. Inherited thrombophilia and preeclampsia within a multicenter cohort: the Montreal Preeclampsia Study.

Kleiman, Lawrence

--Guo, F., Saadatmand, J., Niu, M., and Kleiman, L. Roles of Gag and NCp7 in facilitating tRNAL^{ys3} annealing to viral RNA in HIV-1. *J. Virol.* 83: 8099-8107, 2009

--Saadatmand, J., Niu, M., Kleiman, L., and Guo, F. The contribution of the primer activation signal to differences between Gag- and NCp7-facilitated tRNAL^{ys3} annealing in HIV-1. *Virology* 391:334-341, 2009

--Cen, S., Guo, F., and Kleiman, L. Methods for analysis of incorporation and annealing of tRNAL^{ys3} in HIV-1. in: HIV Protocols: Second Edition. V.R. Prasad and G.V. Kalpana (eds.). Humana Press, 485: 223-232, 2009

Langleben, David

--Star G, Giovinazzo M, **Langleben D**. Effects of bone morphogenic proteins and transforming growth factor beta on in vitro production of endothelin-1 by human pulmonary microvascular endothelial cells. *Vascul Pharmacol*, 50:45-50, 2009

--**Langleben D**, Cacoub P. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade. *Eur J Clin Invest*, 39(S2);39(S2):27-31, 2009

--Looper KJ, Pierre A, Dunkley DM, Sigal JJ, **Langleben D**. Depressive symptoms in relation to physical functioning in pulmonary hypertension. *J Psychosom Res*, in press.

--Simonneau G, Robbins IM, Beghetti M, Channick RC, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, **Langleben D**, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol*, 54:S43-S54, 2009

Lehoux, Stephanie

--Ramkhelawon B, Vilar J, Rivas D, Mees B, De Crom R, Tedgui A, **Lehoux S**. Shear stress regulates angiotensin type one receptor expression in endothelial cells. *Circ Res*, 105: 869-875, 2009

--Csiszar A, **Lehoux S**, Ungvari Z. Hemodynamic forces, vascular oxidative stress and regulation of BMP-2/4 expression. *Antioxid Redox Signal*, 11:1683-1697, 2009

--Castier Y, Ramkhelawon B, Riou S, Tedgui A, **Lehoux S**. Role of NFkappaB in flow-induced vascular remodeling. *Antioxid Redox Signal*, 11:1641-1649, 2009

Lin, Rongtuan

--Nakhaei P, Hiscott J and **Lin R***. Sting-ing The Antiviral Pathway. *Journal of Molecular Cell Biology*, 1-3. 2009

--Li S, Zhang D, Yang L, Burnier JV, Wang N, **Lin R**, Lee ER, Glazer RI, Brodt P. The IGF-I Receptor Can Alter the Matrix Metalloproteinase Repertoire of Tumor Cells through Transcriptional Regulation of PKC- α . *Mol Endocrinol*. 23:12:2013-25, 2009

--Nakhaei P, Mesplede T, Sun Q, Solis M, Zhao T, Yang L, Wilkinson P, Chuang T, Ware C, Lin R and Hiscott J. The E3 ubiquitin ligase Triad3A negatively regulates the RIG-I/MAVS signaling pathway by targeting TRAF3 for degradation. *PLoS Pathog*. Nov;5:11:e1000650, 2009

--Vitour D, Dabo S, Ahmadi Pour M, Vilasco M, Vidalain PO, Jacob Y, Mezel-Lemoine M, Paz S, Arguello M, **Lin R**, Tangy F, Hiscott J, Meurs EF. Polo-like kinase 1 (PLK1) regulates IFN induction by MAVS. *J Biol Chem*. 14:284:33:21797-809, 2009

--Yang L, Zhao T, Nakhaei P, Sun Q, Hiscott J and **Lin R***. Functional Analysis of A Dominant Negative Mutation of Interferon Regulatory Factor 5. *PLoS One*. 4:5:e5500, 2009

--Paz S, Vilasco M, Arguello M, Sun Q, Lacoste J, Nguyen T, Zhao T, Shestakova E, Zaari S, **Lin R**, Meurs E and Hiscott J. Negative regulation of NF-kB signaling pathway by ubiquitination-dependent recruitment of IKKe to MAVS signaling adapter. *Mol Cell Biol*. 29:12:3401-12, 2009

--Génin P, **Lin R**, Hiscott J and Civas A. Opposite transcriptional effects of interferon regulatory factor 3 on differential human interferon- α gene expression. *Mol Cell Biol*. 29:12:3435-50, 2009

--Goubau D, Romieu-Mourez R, Solis M, Hernandez E, Mesplède T, **Lin R**, Leaman D, and Hiscott J. Transcriptional re-programming of primary macrophages reveals distinct apoptotic and anti-tumoral functions of IRF-3 and IRF-7. *Eur J Immunol*. 39:2:527-40. 2009

Lipman, Mark

--Birnbaum LM, **Lipman M**, Paraskevas S, Chaudhury P, Tchervenkov J, Baran D, Herera-Gayol A, Cantarovich M. Management of chronic allograft nephropathy: A systematic review. *Clin J Am Soc Nephrol*, 4:860-865, 2009

MacNamara, Elizabeth

--Thibeault, D., Su, H., **MacNamara, E.**, Schipper, H.M. Isocratic rapid liquid chromatographic method for simultaneous determination of carotenoids, retinol, and tocopherols in human serum. *Journal of Chromatography, B* 877:11-12:1077-1083, 2009

Miller, Mark

--Gravel D, **Miller M**, Simor A, et al and the Canadian Nosocomial Infection Surveillance Program. Health Care-Associated Clostridium difficile infection in Adults admitted to acute care hospitals in Canada: A Canadian Nosocomial Infection Surveillance Program Study. *CID*, 48:568-576, 2009

--Gravel D, Gardam M, Taylor G, **Miller M** et al and the Canadian Nosocomial Infection Surveillance Program. Infection control practices related to Clostridium difficile infection in acute care hospitals in Canada. *AJIC*, 37:9-14, 2009

--**Miller M**. The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy. *Anaerobe*, 281-284, 2009

--Mak A, **Miller MA**, Chong G, Monczak Y. Comparison of PCR and culture for screening of Vancomycin-resistant Enterococci: Highly disparate results for vanA and vanB. *J of Clin Micro*, 47:12:4136-4137, 2009

Miller Jr., Wilson H.

-- Eisen T, Thatcher N, Leyvraz S, **Miller WH Jr**, Couture F, Lorigan P, Lüthi F, Small D, Tanovic A, O'Brien M. Phase II Study of Weekly Plitidepsin as Second-Line Therapy for Small Cell Lung Cancer. *Lung Cancer*, 64:60-5, 2009

--Laurenzana A, Petrucci LA, Pettersson F, Figueroa ME, Melnick A, Baldwin AS, Paoletti F, **Miller WH Jr**. Inhibition of DNA methyltransferase activates TNF-induced monocytic differentiation in acute myeloid leukemia cells. *Cancer Res*, 69: 55-64, 2009

--Robitaille L, Mamer OA, **Miller WH Jr**, Levine M, Assouline S, Melnychuk D, Rousseau C, Hoffer LJ. Oxalic acid excretion after intravenous ascorbic acid administration. *Metabolism*, 58:263-9, 2009

--Batist G, Gelmon KA, Chi KN, **Miller WH Jr**, Chia SKL, Mayer LD, Swenson CE, Janoff AS, Louie AC. Safety, Pharmacokinetics and Efficacy of CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection in Patients With Advanced Solid Tumors. *Clin Cancer Res*, 15:692-700, 2009

-- Eisen T, Thomas J, **Miller WH Jr**, Gore M, Wolter P, Kavan P, López Martín JA, and Lardelli P. Phase II Study of Biweekly Plitidepsin as Second-Line Therapy in Patients with Advanced Malignant Melanoma. *Melanoma Research*, 19:185-192, 2009

--Trottier C, Colombo M, Mann K, **Miller Jr WH**, and Ward B. Retinoids inhibit measles virus through a type I IFN-dependent bystander effect. *The FASEB J.*, 23:3203-3212, 2009

--Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, **Miller WH Jr** and Borden K. Molecular targeting of the oncogene eIF4E in AML: a proof-of-principle clinical trial with ribavirin. *Blood*, 114:257-260, 2009

--Mann KK, Wallner B, Lossos IS, **Miller WH Jr.**, Darinaparsin: a novel organic arsenical with promising anticancer activity. *Expert Opin Investig Drugs*, 18:1727-34, 2009

Nessim, Sharon

--Nessim SJ, Bargman JM, Austin PC, Story K, Jassal SV. Impact of age on peritonitis in peritoneal dialysis patients: an era effect. *Clin J Am Soc Nephrol*, 4:135-41, 2009

--**Nessim SJ**, Bargman JM, Austin PC, Nisenbaum R, Jassal SV. Predictors of peritonitis among patients on peritoneal dialysis: results of a large, prospective Canadian database. *Clin J Am Soc Nephrol*, 4:1195-2000, 2009

Oughton, Matthew

--**Oughton MT**, Loo V, Dendukuri N, Fenn S, Libman M. Plain soap and water are superior to alcohol rub and antiseptic wipes for removal of *Clostridium difficile* by handwashing. *Infection Control and Hospital Epidemiology*, 30:10:939-44, 2009

--**Oughton MT**, **Dascal A**. Acute Infectious Diarrhea. In: *Conn's Current Therapy*, 2009 edition (Elsevier; St. Louis, MO), pp 13-20, 2009

--Gravel D, **Miller M**, Simor A, et al and the Canadian Nosocomial Infection Surveillance Program. Health Care-Associated *Clostridium difficile* infection in Adults admitted to acute care hospitals in Canada: A Canadian Nosocomial Infection Surveillance Program Study. *CID*, 48:568-576, 2009

Pantopoulos, Kostas

--Zukor H, Song W, Liberman A, Mui J, Vali H, Guerquin-Kern J.-L, Fillebeen C, **Pantopoulos K.** and Schipper H. M. HO-1-mediated iron deposition: A mechanism for unregulated iron deposition in aging and degenerating neural tissues, *J. Neurochem.* 109:776-791, 2009

--Sebastiani G and **Pantopoulos K.** Iron metabolism and disease, *Cellular and Molecular Biology of Metals* (eds. Zalups R. K. and Koropatnick J.) Taylor & Francis, pp. 351-378, 2009

Pollak, Michael

--Okereke OI, Selkoe DJ, **Pollak MN**, Stampfer MJ, Hu FB, Hankinson SE, Grodstein F. A profile of impaired insulin degradation in relation to late-life cognitive decline: A preliminary investigation. *Int J Geriatr Psychiatry* 24: 177-82, 2009

--Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, **Pollak MN**, Giovannucci EL, Fuchs CS. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. *J Clin Oncol* 27: 176-85, 2009

--Sinotte M, Diorio C, Berube S, **Pollak M**, Brisson J. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. *Am J Clin Nutr* 89: 634-40, 2009

--Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, **Pollak M.** Insulin receptor expression by human prostate cancers. *The Prostate* 69: 33-40, 2009

--**Pollak M.** Energy metabolism, cancer risk, and cancer prevention. *Recent Results Cancer Res* 181: 51-4, 2009

--Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, Zakikhani M, Carboni JM, Gottardis M, Giunti A, **Pollak M**, Vigneri R, Baldini N. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. *Cancer Res* 69: 2443-52, 2009

--**Pollak, M.** Aging, IGF-1, and diet. *Aging Cell* 8: 214, 2009

--Kaplan RC, Fitzpatrick AL, **Pollak MN**, Gardner JP, Jenny NS, McGinn AP, Kuller LH, Strickler HD, Kimura M, Psaty BM, Aviv A. Insulin-like growth factors and leukocyte telomere length: the cardiovascular health study. *J Gerontol A Biol Sci Med Sci* 64: 1103-6, 2009

--**Pollak, M.** Do cancer cells care if their host is hungry? *Cell Metab* 9: 401-3, 2009

--Rohrman S, Sutcliffe CG, Bienstock JL, Monsegue D, Akereyeni F, Bradwin G, Rifai N, **Pollak MN**, Agurs-Collins T, Platz EA. Racial variation in sex steroid hormones and the insulin-like growth factor axis in umbilical cord blood male neonates. *Cancer Epidemiol Biomarkers Prev* 18: 1484-91, 2009

--Mavropoulos JC, Buschemeyer WC 3rd, Tewari AK, Fokhfeld D, **Pollak M**, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, Pizzo SV, Freedland SJ. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. *Cancer Prev Res (Phila Pa)* 2: 557-65, 2009

--Dowling RJ, **Pollak M**, Sonenberg N. Current status and challenges associated with targeting mTOR for cancer therapy. *Bio Drugs* 23: 77-91, 2009

--Su X, Colditz GA, Willett WC, Collins LC, Schnitt SJ, Connolly JL, **Pollak MN**, Rosner B, Tamimi RM. Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease. *Int J Cancer* 126: 180-90, 2009

--Gualberto A, **Pollak M**. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. *Oncogene* 28: 3009-21, 2009

--**Pollak M**. Macronutrient intake and cancer: how does dietary restriction influence tumor growth and why should we care? *Cancer Prev Res (Phila Pa)* 2: 698-701, 2009

--Beauchamp MC, Knafo A, Yasmeen A, Carboni JM, Gottardis MM, **Pollak MN**, Gotlieb WH. BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. *Gynecol Oncol* 115: 193-8, 2009

--Gualberto A, **Pollak M**. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. *Curr Drug Targets* 10: 923-36, 2009

--Karp DD, **Pollak MN**, Cohen RB, Eisenberg PD, Haluska P, Yin D, Lipton A, Demers L, Leitzel K, Hixon ML, Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ, Gualberto A. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor Figitumumab (CP-751,871) in combination with Paclitaxel and Carboplatin. *J Thorac Oncol* 4: 1397-403, 2009

--Barbieri M, Paolisso G, Kimura M, Gardner JP, Boccardi V, Papa M, Hjelmberg JV, Christensen K, Brimacombe M, Nawrot TS, Staessen JA, **Pollak MN**, Aviv A. Higher circulating levels of igf-1 are associated with longer leukocyte telomere length in healthy subjects. *Mech Ageing Dev* 130: 771-6, 2009

Ponka, Premysl

--Jeong SY, Rathore KI, **Ponka P**, Arosio P, David S. Dysregulation of iron homeostasis in CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. *J Neurosci* 29: 610-609, 2009

--Soe-Lin S, Andriopoulos B, Andrews MC, Schranzhofer M, Kahawita T, Garcia-Santos D, Apte S, **Ponka P**. Nramp1 promotes efficient macrophage recycling of iron following erythrophagocytosis in vivo. *Proc Natl Acad Sci USA* 106:5960-5965, 2009

--Lu Z, Nie G, Li Y, Soe-Lin S, Tao Y, Cao Y, Zhang Z, Liu N, **Ponka P**, Zhao B. Overexpression of mitochondrial ferritin sensitizes cells to oxidative stress via an iron-mediated mechanism. *Antioxid Redox Signal*. 11:1791-1803, 2009

--Peslova G, Petrak J, Kuzelova K, Hrdy I, Halada P, Kuchel PW, Soe-Lin S, **Ponka P**, Sutak R, Becker E, Huang ML, Rahmanto YS, Richardson DR, Vyoral D. Heparin, the hormone of iron metabolism, is bound specifically to α -2-macroglobulin in blood. *Blood*. 113:6225-6236, 2009

--Huang M, Becker E, Whitnall M, Suryo Rahmanto Y, **Ponka P***, Richardson D. Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. *Proc Natl Acad Sci USA*. 106:16381-16386, 2009 *Corresponding author.

--Sheftel AD, Richardson DR, Prchal JT, **Ponka P**. Mitochondrial iron metabolism and sideroblastic anemia (Invited Review; peer reviewed) *Acta Haematol*, 122:120-133, 2009

--Schipper HM, **Ponka P**. Inherited disorders of brain iron metabolism. In Iron Deficiency and Overload: From Basic Biology to Clinical Medicine (Yehuda S, Mostofsky DI eds.), Humana Press Inc, Totowa, NJ, pp. 251-276, 2009

Richards, Brent

--**JB Richards**, D Waterworth, S O'Rahilly, MF Hivert, RJF Loos, JRB Perry, T Tanaka, NJ Timpson, RK Semple, N Soranzo, K Song, N Rocha, E Grundberg, J Dupuis, JC Florez, C Langenberg, I Prokopenko, R Saxena, R Sladek, Y Aulchenko, D Evans, G Waeber, J Erdmann, M-S Burnett, N Sattar, J Devaney, C Willenborg, GIANT Consortium, A Hingorani, JCM Witteman, P Vollenweider, C Hengstenberg, L Ferrucci, D Melzer, K Stark, J Deanfield, J Winogradow, M Grassl, AS Hall, JM Egan, JR Thompson, SL Ricketts, IR König, W Reinhard, S Grundy, H-E Wichmann, P Barter, R Mahley, A Kesaniemi, DJ Rader, MP Reilly, SE Epstein, AFR Stewart, CM Van Duijn, H Schunkert, K Burling, P Deloukas, T Pastinen, NJ Samani, R McPherson, G Davey Smith, TM Frayling, NJ Wareham, JB Meigs, V Mooser,* TD Spector.* A genome-wide association study reveals variants in ARL that influence adiponectin levels. *PLoS Genetics*, 5:12, 2009

--**JB Richards**, FK Kavvoura, F Rivadeneira, U Styrkársdóttir, K Estrada, BV Halldórsson, Y Hsu, MC Zillikens, SG Wilson, BH Mullins, NA MSc, YS Aulchenko, LA Cupples, P Deloukas, S Demissie, A Hofman, A Kong, D Karasik, JB van Meurs, BA Oostra, HA Pols, G Sigurdsson, U Thorsteinsdóttir, N Soranzo, FM Williams, Y Cupples, SH Ralston, G Thorleifsson, CM van Duijn, DP Kiel, KS MD, AG Uitterlinden, JP Ioannidis, TD Spector, A Systematic Evaluation of 150 Candidate Genes for their Association with Osteoporosis and Osteoporotic Fracture in a Meta-Analysis of Genome-Wide Association Data. *Annals of Internal Medicine*, 151:528-537, 2009

--F Rivadeneira,* U Styrkársdóttir,* K Estrada,* B Halldórsson,* YH Hsu,* **JB Richards**,* MC Zillikens,* FK Kavvoura, N Amin, YS Aulchenko, LA Cupples, P Deloukas, S Demissie, E Grundberg, A Hofman, A Kong, D Karasik, JB van Meurs, B Oostra, T Pastinen, HA Pols, G Sigurdsson, N Soranzo, G Thorleifsson, U Thorsteinsdóttir, FMK Williams, SG Wilson, Y Zhou, SH Ralston, CM van Duijn, T Spector, DP Kiel, K Stefansson, JPA Ioannidis, AG Uitterlinden, for the

GEFOS Consortium. Twenty bone mineral density loci identified by large-scale meta-analysis of genome-wide association studies. *Nature Genetics*, 41:1199-206, 2009

--M Mangino*, **JB Richards***, N Soranzo, G Zhai, A Aviv, AM Valdes, NJ Samani, P Deloukas, TD Spector. A genome-wide association study identifies a novel locus on chromosome 18q12.2 influencing white cell telomere length. *Journal of Medical Genetics*. 46:451-4, 2009

--N Soranzo,* F Rivadeneira,* U Chinappen-Horsley,* I Malkina, **JB Richards**, N Hammond, L Stolk, A Nica, M Inouye, A Hofman, J Stephens, E Wheeler, P Arp, R Gwilliam, PM Jhamai, S Potter, A Chaney, MJR Ghorri, R Ravindrarajah, S Ermakov, K Estrada, H AP Pols, FM. Williams, WL McArdle, JB van Meurs, RJF. Loos, ET. Dermitzakis, KR Ahmadi, DJ Hart, WH Ouwehand, NJ Wareham, I Barroso, MS Sandhu, DP Strachan, G Livshits, TD Spector, AG Uitterlinden, P Deloukas. Meta-analysis of genome-wide scans for human adult stature in humans identifies novel loci and differential effects with measures of skeletal frame size. *PLoS Genetics*, 5:1-13, 2009

--NJ Timpson, JH Tobias, **JB Richards**, EL Duncan, AM Sims, N Soranzo, P Whittaker, V Kumanduri, G Zhai, B Glaser, J Eisman, Graeme Jones, Geoff Nicholson, R Prince, E Seeman, TD Spector, MA Brown, L Peltonen, G Davey Smith, P Deloukas, DM Evans. Common variants in the region around Osterix are associated with bone mineral density and growth in childhood. *Human Molecular Genetics*, 18:8:1510-7, 2009

--Skidmore PM, Cassidy A, Swaminathan R, Richards JB, Mangino M, Spector TD, Macgregor AJ. An obesogenic postnatal environment is more important than the fetal environment for the development of adult adiposity: a study of female twins. *American Journal of Clinical Nutrition*. 90:2:401-6, 2009

--G Zhai, JBJ van Meurs, G Livshits, I Meulenbelt, AM Valdes, N Soranzo, D Hart, F Zhang, BS Kato, **JB Richards**, FMK Williams, M Inouye, M Kloppenburg, P Deloukas, E Slagboom, A Uitterlinden, TD Spector. A genome-wide association study suggests that a locus within the ataxin 2 binding protein 1 gene is associated with hand osteoarthritis: the Treat-OA consortium. *Journal of Medical Genetics*, 46:614-6, 2009

--Cassidy A, Skidmore P, Rimm EB, Welch A, Fairweather-Tait S, Skinner J, Burling K, **Richards JB**, Spector TD, Macgregor AJ. Plasma Adiponectin Concentrations Are Associated with Body Composition and Plant-Based Dietary Factors in Female Twins. *Journal of Nutrition*, 139:353-8, 2009

--SG Wilson, MR Jones, BH Mullin, IM Dick, JB Richards, TM Pastinen, E Grundberg, O Ljunggren, GL Surdulescu, F Dudbridge, KS Elliott, AC Cervino, TD Spector, RL Prince, Common sequence variation in FLNB regulates bone structure in women in the general population and FLNB mRNA expression in osteoblasts in vitro. *Journal of Bone and Mineral Research*. 24:1989-97, 2009

Rosenblatt, David

--Rutsch F, Gailus S, Miousse IR, Suormala T, Sagné, Toliat MR, Nurnberg G, Wittkamp T, Buers I, Shariffi A, Stucki M, Becker C, Baumgartner M, Robenek H, Marquardt T, Hohne W, Gasnier B, **Rosenblatt DS**, Fowler B, Nurnberg P. Identification of a putative lysosomal cobalamin exporter mutated in the cblF inborn error of vitamin B₁₂ metabolism. *Nat Genet*, 41:234-239, 2009

--Miousse IR, Watkins D, Lavallée J, Coelho D, Rupa T, Clarke JTR, Crombez EA, Vilain E, Cederbaum S, Bernstein JA, Cowan T, Lee-Messer C, Enns GM, Fowler B, **Rosenblatt DS**. Clinical and molecular heterogeneity in patients with the *cblD* inborn error of cobalamin metabolism. *J Pediatr*, 154: 551-556, 2009

--Loewy AD, Niles KM, Anastasio N, Watkins D, Lavoie J, Lerner-Ellis JP, Pastinen T, Trasler JM, **Rosenblatt DS**. Epigenetic modification of the gene for the vitamin B₁₂ chaperone MMACHC can result in increased tumorigenicity and methionine dependence. *Mol Genet Metab* 96: 261-267, 2009

--Lerner-Ellis JP, Anastasio N, Liu J, Coelho D, Suormala T, Stucki M, Loewy A, Gurd S, Grundberg E, Morel CF, Watkins D, Baumgartner MR, Pastinen T, **Rosenblatt DS**, Fowler B. Spectrum of mutations in MMACHC, allelic expression and evidence for genotype-phenotype correlations. *Human Mutat.*, 30:1072-1081, 2009

--Li, F, Watkins D, **Rosenblatt DS**. Vitamin B₁₂ and birth defects. *Molec. Genet. Metab.* **98**:166-172, 2009

--Hannibal L, Kim J, Brasch NE, Wang S, **Rosenblatt DS**, Banerjee R, Jacobsen DW. Processing of alkylcobalamins in mammalian cells: a role for the MMAC (cblC) gene product. *Molec. Genet. Metab.* 97:260-2166, 2009

--Lin HJ, Neidich JA, Salazar D, Thomas-Johnson E, Ferreira BF, Kwong AM, Lin AM, Jonas AJ, Levine S, Lorey F, **Rosenblatt DS**. Asymptomatic Maternal Combined Homocystinuria and Methylmalonic Aciduria (cblC) Detected through Low Carnitine Levels on Newborn Screening. *J Pediatr*, 155: 924-927, 2009

--Watkins D, Whitehead VM and **Rosenblatt DS**. Megaloblastic anemia in Nathan and Oski's Hematology of Infancy and Childhood (7th ed). Orkin SH, Ginsburg D, Nathan DA, Look AT, Fisher DE (eds). Chapter 11 pp 467-520, 2009

--Morel C and **Rosenblatt DS**. Inborn Errors of Folate and Cobalamin Transport and Metabolism in Pediatric Endocrinology and Inborn Errors of Metabolism. Eds. Sarafoglou K, Hoffman GF and Roth KS. McGraw-Hill Companies. pp 195-212, 2009

Schiffrin, Ernesto L.

--**Schiffrin EL**, Paradis P. Editorial: Suppression of PPAR- γ activity by angiotensin II in vascular smooth muscle involves Bcr kinase: The fire that drowns the water. *Circ Res.* 104:4-6, 2009

--Padwal RS, Hemmelgarn BR, Khan NA, Grover S, McAlister FA, McKay DW, Wilson T, B Penner MD, Burgess E, Bolli P, Hill M, Mahon J, Myers MG, Abbott C, **Schiffrin EL**, Honos G, Mann K, Tremblay G, Milot A, Cloutier L, Chockalingam A, Rabkin SW, Dawes M, Touyz RM, Bell C, Lebel M, Tobe SW, for the Canadian Hypertension Education Program. The 2009 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: Part I - Blood pressure measurement, diagnosis, and assessment of risk. *Can J Cardiol* 25:279-286, 2009

--Khan NA, Hemmelgarn BR, Herman RJ, Leiter LA, Mahon JL, Bell CM, Rabkin SW, Hill MD, Touyz RM, Padwal RS, Larochelle P, Feldman RD, **Schiffrin EL**, Campbell NRC, Arnold MO, Moe G, Campbell TS, Milot A, Stone JA, Jones C, Ogilvie RI, Hamet P MD, Fodor G, Carruthers G, Burns KD, Prasad R, Ruzicka M, deChamplain J, Pylypchuk G, Petrella R, Boulanger J-M, Trudeau L, Hegele RA, Woo V, McFarlane P, Vallée M, Howlett J, Katzmarzyk P, Lewanczuk RZ, Tobe S for the Canadian Hypertension Education Program. The 2009 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: Part 2- Therapy. *Can J Cardiol* 25:287-298, 2009

--Javeshgani D, **Schiffrin EL**, Sairam MR, Touyz RM. Potentiation of Vascular Oxidative Stress and nitric oxide-mediated Endothelial Dysfunction by High Fat Diet in a Mouse Model of Estrogen Deficiency and Hyperandrogenemia. *J Amer Soc Hypert.* 3:295-305, 2009

--**Schiffrin EL**. In Memoriam: Jacques de Champlain, M.D., Ph.D. *Hypertension.* 54:689, 2009

--Leibovitz E, Ebrahimian T, Paradis P, **Schiffrin EL**. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. *J Hypertens.* 27:2192-2200, 2009

--Lemarié CA, Nikonova A, Simeone S, Ebrahimian T, Deschênes M-E, Paradis P, **Schiffrin EL**. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. *Circ Res.* 105;852-859, 2009

--Marchesi C, Ebrahimian T, Angulo O, Paradis P, **Schiffrin EL**. Endothelial NO synthase uncoupling and perivascular adipose oxidative stress and inflammation contribute to vascular dysfunction in a rodent model of metabolic syndrome. *Hypertension.* 54:1384-1392, 2009

--Abourbih S, Fillion KB, Joseph L, **Schiffrin EL**, Rinfret S, Poirier P, Pilote L, Genest J, Eisenberg M J. Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review of Randomized Controlled Trials. *Amer J Med.* 122:962.e1-962.e8, 2009

Schweitzer, Morris

--Gottlieb B, Chalifour LE, Mitmaker B, Sheiner N, Obrand D, Abraham C, Meilleur M, Sugahara T, Bkaily G, **Schweitzer M**. BAK1 Gene Variation and Abdominal Aortic Aneurysms. *Human Mutations.* 30:1043-1047, 2009

--**Schweitzer M**, Mitmaker B, Obrand D, Sheiner N, Abraham C, Dostanic S, Chalifour LE. Atorvastatin mediates increases in intralésional BAX and BAK expression in human end-stage abdominal aortic aneurysms. *Canadian Journal of Physiology and Pharmacology*. 87:915-922, 2009

Sheppard, Richard

--**Sheppard R**. Vascular Genomics of Hypertension. *Heart Failure Clinics of North America* 255, Volume 6, 2009

Suissa, Samy

--**Suissa S**, Delaney JA. The case-crossover study design in pharmacoepidemiology. *Stat Methods Med Res*, 18(1):53-65, 2009

--Sears MR, Ottosson A, Radner F, **Suissa S**. Long-acting β -agonists: a review of formoterol safety data from asthma clinical trials. *Eur Respir J*, 33(1):21-32, 2009

--Delaney JA, Daskalopoulou SS, **Suissa S**. Traditional versus marginal structural models to estimate the effectiveness of beta-blocker use on mortality after myocardial infarction. *Pharmacoepidemiol Drug Safety*, 18(1):1-6, 2009

--**Suissa S**. [Editorial]. Statistical methods in pharmacoepidemiology: advances and challenges. *Stat Methods Med Res*, 18(1):3-6, 2009

--Brassard P, Lowe AM, Bernatsky S, Kezouh A, **Suissa S**. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. *Arthritis Rheum*, 61(3):300-304, 2009

--Bernier MO, Mikaeloff Y, Hudson M, **Suissa S**. Combined oral contraceptive use and the risk of systemic lupus erythematosus. *Arthritis Rheum*, 61(4):476-481, 2009

--**Suissa S**. Controverses méthodologiques sur les essais thérapeutiques dans la bronchopneumopathie chronique obstructive. *Presse Médicale*, 38(3):445-451, 2009

--Mikaeloff Y, Caridade G, **Suissa S**, Tardieu M. Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. *Neurol*, 72(10):873-880, 2009

--Andersohn F, Schade R, **Suissa S**, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. *Am J Psychiatry*, 166(5):591-598, 2009

--**Suissa S**. The transnational study of oral contraceptive cardiovascular safety: history and science. *J Clin Epidemiol*, 62(6):588-593, 2009

--**Suissa S**, Dell'Aniello S, Ernst P. Effectiveness of combination therapies in asthma: An observational study. *Pulm Pharmacol Therapeut*, 22(3):194-198, 2009

--Mauer M, Zinman B, Gardiner R, **Suissa S** et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. *N Engl J Med*, 361(1):40-51, 2009

--Mikaeloff Y, Caridade G, **Suissa S**, Tardieu M; on behalf of the KIDSEP Study Group. Clinically observed chickenpox and the risk of childhood-onset multiple sclerosis. *Am J Epidemiol*, 169(10):1260-1266, 2009

--Delaney JA, Platt RW, **Suissa S**. The impact of unmeasured baseline effect modification on estimates from an inverse probability of treatment weighted logistic model. *Eur J Epidemiol*, 24(7):343-349, 2009

--Fillion KB, Joseph L, Boivin JF, **Suissa S**, Brophy JM. Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. *Pharmacopidemiol Drug Saf*, 18(10):973-976, 2009

--Simon TA, Smitten AL, Franklin J, Askling J, Lacaille D, Wolfe F, Hochberg MC, Qi K, **Suissa S**. Malignancies in the rheumatoid arthritis abatacept clinical development program: An epidemiological assessment. *Ann Rheumatol Dis*, 68(12):1819-1826, 2009

Szilagyi, Andrew

--**A Szilagyi**, I Shrier, G Chong JS Je, SH Park D Heilpern Lalonde C, L-F Cote, B Lee. Lack of effect of lactose digestion status on quantitative fecal microflora. *Can J Gastroenterol*, 23:753-759, 2009

--M. Almadi , PM. Ghali , A Constantin ,J Galipeau , **A Szilagyi**. Recurrent obscure gastrointestinal bleeding: Dilemmas and Success with pharmacologic therapies, case series and review. *Can J Gastroenterol*, 23:625-631, 2009

--**A Szilagyi**. Functional Disaccharides in Handbook of Pre and Probiotics Ingredients. Health Benefits and Food Applications. Cho Susan S and Finocchiaro E Terry eds, CRC press, Taylor and Francis Group. Boca Raton, Florida USA. 95-122, 2009

Therrien, Judith

--Tzemos N, Silversides CK, Colman JM, **Therrien J**, Webb GD, Mason J, Cocoara E, Sermer M, Sui SC. Late cardiac outcomes after pregnancy in women with congenital aortic stenosis. *Am Heart J*, 157:474-80, 2009

--Mackie A, Ionescu-Ittu R, **Therrien J**, Pilote R, Marelli AJ. Children and adults with congenital heart disease lost to follow up: who and when? A population-based study. *Circulation*, 120:302-309, 2009

--Bouchardy J. **Therrien J**, Martucci G, Marelli A. Atrial Fibrillation Doubles Adverse Events in Adult with Congenital Heart Disease. *Accepted Circulation* 2009

Tischkowitz, Marc

--**Tischkowitz MD**, Sabbaghian N, Hamel N, Borgida A, Rosner C, Taherian N, Srivastava A, Holter S, Rothenmund H, Ghadirian P, **Foulkes WD**, Gallinger S. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. *Gastroenterology*, 137(3):1183-6, 2009

Wassmann, Sven

--Litvinov IV, Kotowycz MA, **Wassmann S**. Iatrogenic epinephrine-induced reverse takotsubo cardiomyopathy: direct evidence supporting the role of catecholamines in the pathophysiology of the "broken heart syndrome". *Clin Res Cardiol*, 98:457-462, 2009

--Atar D, Carmena R, Clemmensen P, K-Laflamme A, **Wassmann S**, Lansberg P, Hobbs R. Clinical review: Impact of statin substitution policies on patient outcomes. *Ann Med*, 41:242-256, 2009

Zaharatos, G. Jerry

--**Zaharatos, G.J.** 2008. Cryptosporidium. In A.R. Satoskar, G. Simon, P. Hotez, and M. Tsuji (Eds.), Parasitology. Georgetown, Texas: Landes Bioscience, pp214-221, 2009

215 publications